Mesoblast Limited has achieved full patient recruitment for its Phase 3 pivotal trial evaluating rexlemestrocel-L as a treatment for chronic low back pain associated with degenerative disc disease. The milestone represents a critical step toward bringing a non-opioid therapy to a massive market with significant unmet medical need. With chronic low back pain affecting more than 7 million people in the US alone, and the indication representing a potential blockbuster market with estimated peak year revenues exceeding USD 10 billion at single-digit market penetration, this trial advancement carries substantial implications for Mesoblast’s growth trajectory and competitive positioning.
The randomized, placebo-controlled Phase 3 trial, designated MSB-DR004, enrolled over 300 patients who received either a single intra-discal injection of rexlemestrocel-L or sham control, with patients to be followed for 12 months. The company’s proprietary allogeneic stromal cell product targets the inflammatory processes underlying disc degeneration. The trial’s primary endpoint is designed to demonstrate significant pain reduction at 12 months compared to sham controls, while secondary endpoints include improvements in function, quality of life, and medication cessation, with particular emphasis on opioid reduction. This focus is clinically significant given that discogenic back pain accounts for approximately 50 percent of prescription opioid usage in the United States.
The current Phase 3 trial builds on encouraging results from the earlier MSB-DR003 study, where a single injection of rexlemestrocel-L produced clinically meaningful reductions in pain and opioid usage that persisted for up to three years. The FDA has already agreed to the trial design and accepted the 12-month pain reduction endpoint as approvable for regulatory purposes. Rexlemestrocel-L also carries Regenerative Medicine Advanced Therapy designation from the FDA, which provides eligibility for priority review once a Biologics License Application is filed, potentially accelerating the regulatory pathway compared to standard review timelines.
Mesoblast anticipates top-line results from the trial in mid-2027 after the final patient completes 12 months of follow-up. A positive readout would support an expected regulatory filing with the FDA in the third quarter of 2027. The combination of previous positive trial data, full patient recruitment, a validated trial design, and expedited regulatory pathways creates a clear timeline toward potential approval and commercialization. Investors should monitor trial progress announcements and any interim data releases that might signal the strength of efficacy outcomes.
The catalyst timeline suggests potential inflection points throughout 2027 as the company moves from current enrollment completion to data readout to regulatory submission. Given the magnitude of the addressable market and the significant unmet need for non-opioid chronic low back pain treatments, positive Phase 3 results could position rexlemestrocel-L as a transformative therapy. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
